Archbold Cardiologists offer a breakthrough treatment for chronic limb-threatening
ischemia below-the-knee.
Esprit™ BTK System is a first-of-its-kind dissolvable stent comprised
of material similar to a dissolving suture. It is designed to keep arteries
open and deliver a drug called Everolimus to support vessel healing prior
to completely dissolving.
Peripheral arterial disease (PAD) is highly prevalent, yet many people
have never heard of the condition. In fact, more than 20 million people
in the U.S. are living with this painful disease and only 10% of them
have been diagnosed.
Chronic limb-threatening ischemia (CLTI) below-the-knee (BTK) is a serious
form of PAD that occurs when arteries become clogged with plaque, preventing
blood flow and oxygen from reaching the lower leg and foot. People living
with CLTI often experience extreme pain, open wounds that don’t
heal and may even require amputation. Over a five-year period, CLTI has
a lower survival rate than breast, colorectal, and prostate cancer combined.
Blockages treated only with balloon angioplasty, the previous standard
of care, have poor short- and long-term results, and in many instances
the vessels become blocked again, requiring additional treatment.
Esprit™ BTK System is designed to keep arteries open and deliver
a drug to support vessel healing prior to completely dissolving.
The device is implanted during a catheter-based, minimally invasive procedure
via a small incision in the leg. Once the blockage is open, the Esprit™
BTK helps heal the vessel and provides support for approximately three
years until the vessel is strong enough to remain open on its own.
In the News: Archbold Vascular Procedure is First FDA-Approved Case in Georgia
CardiologyView Profile
.jpg)
